230 related articles for article (PubMed ID: 9346890)
1. Purification and cloning of hepatocyte growth factor activator inhibitor type 2, a Kunitz-type serine protease inhibitor.
Kawaguchi T; Qin L; Shimomura T; Kondo J; Matsumoto K; Denda K; Kitamura N
J Biol Chem; 1997 Oct; 272(44):27558-64. PubMed ID: 9346890
[TBL] [Abstract][Full Text] [Related]
2. Multiple sites of proteolytic cleavage to release soluble forms of hepatocyte growth factor activator inhibitor type 1 from a transmembrane form.
Shimomura T; Denda K; Kawaguchi T; Matsumoto K; Miyazawa K; Kitamura N
J Biochem; 1999 Nov; 126(5):821-8. PubMed ID: 10544273
[TBL] [Abstract][Full Text] [Related]
3. Hepatocyte growth factor activator inhibitor, a novel Kunitz-type serine protease inhibitor.
Shimomura T; Denda K; Kitamura A; Kawaguchi T; Kito M; Kondo J; Kagaya S; Qin L; Takata H; Miyazawa K; Kitamura N
J Biol Chem; 1997 Mar; 272(10):6370-6. PubMed ID: 9045658
[TBL] [Abstract][Full Text] [Related]
4. Tissue expression, protease specificity, and Kunitz domain functions of hepatocyte growth factor activator inhibitor-1B (HAI-1B), a new splice variant of HAI-1.
Kirchhofer D; Peek M; Li W; Stamos J; Eigenbrot C; Kadkhodayan S; Elliott JM; Corpuz RT; Lazarus RA; Moran P
J Biol Chem; 2003 Sep; 278(38):36341-9. PubMed ID: 12815039
[TBL] [Abstract][Full Text] [Related]
5. Mouse hepatocyte growth factor (HGF) activator inhibitor type 2 lacking the first Kunitz domain potently inhibits the HGF activator.
Kataoka H; Itoh H; Nuki Y; Hamasuna R; Naganuma S; Kitamura N; Shimomura T
Biochem Biophys Res Commun; 2002 Jan; 290(3):1096-100. PubMed ID: 11798188
[TBL] [Abstract][Full Text] [Related]
6. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 1.
Denda K; Shimomura T; Kawaguchi T; Miyazawa K; Kitamura N
J Biol Chem; 2002 Apr; 277(16):14053-9. PubMed ID: 11805118
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte growth factor activator inhibitor type 2 lacking the first Kunitz-type serine proteinase inhibitor domain is a predominant product in mouse but not in human.
Itoh H; Kataoka H; Hamasuna R; Kitamura N; Koono M
Biochem Biophys Res Commun; 1999 Feb; 255(3):740-8. PubMed ID: 10049781
[TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor activation inhibitors (HAI-1 and HAI-2) regulate HGF-induced invasion of human breast cancer cells.
Parr C; Jiang WG
Int J Cancer; 2006 Sep; 119(5):1176-83. PubMed ID: 16557597
[TBL] [Abstract][Full Text] [Related]
9. Functional characterization of Kunitz domains in hepatocyte growth factor activator inhibitor type 2.
Qin L; Denda K; Shimomura T; Kawaguchi T; Kitamura N
FEBS Lett; 1998 Sep; 436(1):111-4. PubMed ID: 9771903
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of HGF activator inhibitor type 1 but not type 2 along with regeneration of intestinal mucosa.
Itoh H; Kataoka H; Tomita M; Hamasuna R; Nawa Y; Kitamura N; Koono M
Am J Physiol Gastrointest Liver Physiol; 2000 Apr; 278(4):G635-43. PubMed ID: 10762618
[TBL] [Abstract][Full Text] [Related]
11. The hepatocyte growth factor regulatory factors in human breast cancer.
Parr C; Watkins G; Mansel RE; Jiang WG
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):202-11. PubMed ID: 14734471
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte growth factor activator inhibitor type 1 inhibits protease activity and proteolytic activation of human airway trypsin-like protease.
Kato M; Hashimoto T; Shimomura T; Kataoka H; Ohi H; Kitamura N
J Biochem; 2012 Feb; 151(2):179-87. PubMed ID: 22023801
[TBL] [Abstract][Full Text] [Related]
13. TMPRSS13, a type II transmembrane serine protease, is inhibited by hepatocyte growth factor activator inhibitor type 1 and activates pro-hepatocyte growth factor.
Hashimoto T; Kato M; Shimomura T; Kitamura N
FEBS J; 2010 Dec; 277(23):4888-900. PubMed ID: 20977675
[TBL] [Abstract][Full Text] [Related]
14. Mouse hepatocyte growth factor activator inhibitor type 1 (HAI-1) and type 2 (HAI-2)/placental bikunin genes and their promoters.
Itoh H; Kataoka H; Meng JY; Hamasuna R; Kitamura N; Koono M
Biochim Biophys Acta; 2001 May; 1519(1-2):92-5. PubMed ID: 11406276
[TBL] [Abstract][Full Text] [Related]
15. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells.
Parr C; Jiang WG
Int J Oncol; 2001 Oct; 19(4):857-63. PubMed ID: 11562767
[TBL] [Abstract][Full Text] [Related]
16. Genomic structure and chromosomal localization of the human hepatocyte growth factor activator inhibitor type 1 and 2 genes.
Itoh H; Yamauchi M; Kataoka H; Hamasuna R; Kitamura N; Koono M
Eur J Biochem; 2000 Jun; 267(11):3351-9. PubMed ID: 10824123
[TBL] [Abstract][Full Text] [Related]
17. Roles of functional and structural domains of hepatocyte growth factor activator inhibitor type 1 in the inhibition of matriptase.
Kojima K; Tsuzuki S; Fushiki T; Inouye K
J Biol Chem; 2008 Feb; 283(5):2478-87. PubMed ID: 18048349
[TBL] [Abstract][Full Text] [Related]
18. Conformational lability in serine protease active sites: structures of hepatocyte growth factor activator (HGFA) alone and with the inhibitory domain from HGFA inhibitor-1B.
Shia S; Stamos J; Kirchhofer D; Fan B; Wu J; Corpuz RT; Santell L; Lazarus RA; Eigenbrot C
J Mol Biol; 2005 Mar; 346(5):1335-49. PubMed ID: 15713485
[TBL] [Abstract][Full Text] [Related]
19. Potent inhibition and global co-localization implicate the transmembrane Kunitz-type serine protease inhibitor hepatocyte growth factor activator inhibitor-2 in the regulation of epithelial matriptase activity.
Szabo R; Hobson JP; List K; Molinolo A; Lin CY; Bugge TH
J Biol Chem; 2008 Oct; 283(43):29495-504. PubMed ID: 18713750
[TBL] [Abstract][Full Text] [Related]
20. Possible role of combined therapy targeting MET and pro-HGF activation for renal cell carcinoma: analysis by human HGF-producing SCID mice.
Fujii M; Akioka T; Kimura S; Nagai T; Kiwaki T; Fukushima T; Mukai S; Kamoto T
Hum Cell; 2023 Mar; 36(2):775-785. PubMed ID: 36708441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
